Big pharma is taking big risks in its dealings with biotech, The Wall Street Journal's Jason Douglas says. Pushed by the market to get new products out, pharmaceutical companies are spending less on their own research and more on acquiring experimental compounds from biotech companies, even if they've barely begun to be tested.